ContractFibrogen Inc • June 11th, 2014 • Pharmaceutical preparations • California
THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER, SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT OR RECEIPT OF A NO-ACTION LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION.
ContractFibrogen Inc • June 11th, 2014 • Pharmaceutical preparations • California
THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER, SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT OR RECEIPT OF A NO-ACTION LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION.
INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • June 11th, 2014 • Fibrogen Inc • Pharmaceutical preparations • Delaware
INVESTOR RIGHTS AGREEMENT (the “Agreement”) made and entered into as of February 20, 1998, by and among FIBROGEN, INC., a Delaware corporation (the “Company”), and the parties who have executed this Agreement as Investors (the “Investors”).
LICENSE AGREEMENTLicense Agreement • June 11th, 2014 • Fibrogen Inc • Pharmaceutical preparations • Florida
This Agreement, made and entered into this 23rd day of May, 1997 (the Effective Date”), by and between the UNIVERSITY OF MIAMI and its SCHOOL OF MEDICINE, having its principal office at 1600 N.W. 10th Avenue, Miami, Florida 33136 (hereinafter “LICENSOR”) and FIBROGEN, INC., a corporation duly organized under the laws of Delaware and having its principal office at 260 Littlefield Avenue, South San Francisco, California 94080 and its Affiliates (hereinafter collectively, “FIBROGEN”).
INVESTORS’ RIGHTS AGREEMENT’ Rights Agreement • June 11th, 2014 • Fibrogen Inc • Pharmaceutical preparations • California
THIS INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made as of the 12th day of May, 2000 by and among FibroGen, Inc., a Delaware corporation (the “Company”), and the purchasers of the Company’s Series E Preferred Stock (the “Series E Preferred”) listed on the signature pages hereto (the “Investors”).
LICENSE AGREEMENTLicense Agreement • June 11th, 2014 • Fibrogen Inc • Pharmaceutical preparations • New York
This License Agreement (the “Agreement”), effective, subject to Article 22, upon the Effective Time (as defined in the Agreement and Plan of Merger (the “Merger Agreement”) between Fibrogen, Inc., FGIM Corp, Imigen Systems, Inc. (the “Imigen Acquisition”) (“Effective Date”), is between the Dana-Farber Cancer Institute, Inc., a Massachusetts non-profit organization having a principal place of business at 44 Binney Street, Boston, Massachusetts, 02115 (“DFCI”), and FibroGen, Inc., a Delaware corporation having a principal place of business at 225 Gateway Blvd., South San Francisco, CA 94080 (“LICENSEE”).
FIBROGEN, INC. INVESTORS’ RIGHTS AGREEMENT December 22, 2004Investors’ Rights Agreement • June 11th, 2014 • Fibrogen Inc • Pharmaceutical preparations • California
THIS INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made as of the 22nd day of December, 2004 by and among FibroGen, Inc., a Delaware corporation (the “Company”), and the purchasers of the Company’s Series F Preferred Stock (the “Series F Preferred”) listed on the signature pages hereto (the “Investors”).
AMENDMENT NO. 1 TO RESEARCH AND COMMERCIALIZATION AGREEMENTResearch and Commercialization Agreement • June 11th, 2014 • Fibrogen Inc • Pharmaceutical preparations
THIS AMENDMENT No. 1 TO RESEARCH AND COMMERCIALIZATION AGREEMENT (“Amendment”) is made and entered into effective as of June 30, 2001 (the “Amendment Date”) by and between MEDAREX, INC., 707 State Road, Suite 206, Princeton, NJ 08540, GENPHARM INTERNATIONAL INC., a wholly-owned subsidiary of Medarex, Inc. (together, “Medarex”), and FIBROGEN, INC., a Delaware corporation, 225 Gateway Boulevard, South San Francisco, California 94080 and FIBROPHARMA, INC., a wholly-owned subsidiary of Fibrogen, Inc. (collectively, “FibroGen”). Capitalized terms used in this Amendment that are not otherwise defined herein shall have the same meanings as such terms are defined in the Agreement (as defined below).
INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • June 11th, 2014 • Fibrogen Inc • Pharmaceutical preparations • Delaware
INVESTOR RIGHTS AGREEMENT (the “Agreement”) made and entered into as of February 8, 2000, by and among FIBROGEN, INC., a Delaware corporation (the “Company”), and the parties who have executed this Agreement as Investors (the “Investors”).
AMENDMENT NO. 2 TO LICENSE AGREEMENTLicense Agreement • June 11th, 2014 • Fibrogen Inc • Pharmaceutical preparations
This Amendment No. 2, effective March 14, 2006, to the License Agreement effective upon the Effective Time as amended on February 28, 2006 (the “Agreement”), by and between Dana-Farber Cancer Institute, Inc., and FibroGen, Inc. and its subsidiaries (collectively, the “Parties”). The Parties, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, agree as follows:
Supplementary Agreement to Lease of Premises in Beijing BDA Biomedical ParkSupplementary Agreement • June 11th, 2014 • Fibrogen Inc • Pharmaceutical preparations • Beijing
The Parties have entered into the Lease of Premises in Beijing BDA Biomedical Park (hereinafter referred to as “Contract”) in relation to the premises which are managed by Party B and intended to be rented by Party C. The Parties have agreed to supplement and amend certain terms of the Contract and its Appendix 1 - General Terms of the Lease (hereinafter referred to as “General Terms”) as follows:
ContractLicense Agreement • June 11th, 2014 • Fibrogen Inc • Pharmaceutical preparations
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
SHARE PURCHASE AGREEMENT BY AND AMONG FIBROGEN CHINA ANEMIA HOLDINGS, LTD. AND THE PURCHASERS PARTY HERETO DATED JULY 11, 2012Share Purchase Agreement • June 11th, 2014 • Fibrogen Inc • Pharmaceutical preparations • Delaware
THIS SERIES A PREFERENCE SHARE PURCHASE AGREEMENT is made as of the 11th day of July, 2012 by and among FibroGen China Anemia Holdings, Ltd., a Cayman Islands exempted company limited by shares (the “Company”), and the investors listed on Exhibit A attached to this Agreement (each a “Purchaser” and together the “Purchasers”).
FIBROGEN, INC. AMENDMENT TO STOCK OPTION AGREEMENT GRANTED UNDER 2005 STOCK PLANStock Option Agreement • June 11th, 2014 • Fibrogen Inc • Pharmaceutical preparations
Pursuant to your Election to Participate in FibroGen’s Amendment and Exchange Offer ending on June 24, 2010 (your “Election”), this AMENDMENT (the “Amendment”) is entered into and made effective on June 24, 2010 (the “Amendment Effective Date”) by and between you, [ ] (“Optionee”) and FibroGen, Inc. and its subsidiaries (“Company”). This Amendment amends the Stock Option Agreement that governs the option with Option Grant Number [ ] (now referred to as MA[ ]) granted on [ ] for [ ] shares of FibroGen Common Stock, for which you have agreed to amend pursuant to your executed Election (the “Option Agreement”). Optionee and Company shall be referred to individually herein as a “Party”, and collectively as, the “Parties”. The Option Agreement, together with its corresponding Option Grant Notice and this Amendment are collectively referred to as the “Agreement”.
FIBROGEN, INC. AMENDMENT TO STOCK OPTION AGREEMENT GRANTED UNDER 1999 STOCK PLANStock Option Agreement • June 11th, 2014 • Fibrogen Inc • Pharmaceutical preparations
Pursuant to your Election to Participate in FibroGen’s Amendment and Exchange Offer ending on June 24, 2010 (your “Election”), this Amendment (the “Amendment”) is entered into and made effective on June 24, 2010 (the “Amendment Effective Date”) by and between you, [ ] (“Optionee”) and FibroGen, Inc. and its subsidiaries (“Company”). This Amendment amends the Stock Option Agreement that governs the option with Option Grant Number [ ] (now referred to as MA[ ]) granted on [ ] for [ ] shares of FibroGen Common Stock, for which you have agreed to amend pursuant to your executed Election (the “Option Agreement”). Optionee and Company shall be referred to individually herein as a “Party”, and collectively as, the “Parties”. The Option Agreement, together with its corresponding Option Grant Notice and this Amendment are collectively referred to as the “Agreement”.
